Motexafin Gadolinium OverviewMotexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases. History On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc. On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3 ...
Read more Motexafin Gadolinium Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Motexafin_gadolinium
Recent Motexafin Gadolinium Forums:Be the first to start a discussion about this drug.
Other drugs which contain Motexafin Gadolinium or a similar ingredient: (1 result)
- XCYTRIN Motexafin Gadolinium